PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple negative breast cancer (TNBC)

BACKGROUND: In both the IMpassion 130 trial in the metastatic setting and in Keynote 522 in the neoadjuvant setting, triple negative breast cancer (TNBC) patients showed benefit from PD-1 axis immunotherapy. Here, we assess PD-L1 expression on both tumor and immune cells using quantitative immunoflu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Ahmed, Fahad Shabbir, Gaule, Patricia, McGuire, John, Patel, Katir, Blenman, Kim, Pusztai, Lajos, Rimm, David L.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572612/
https://ncbi.nlm.nih.gov/pubmed/32709714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1303
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires